These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 14991994)

  • 1. [Structure-based design, synthesis and evaluation of bioactivity of anti-P-gp peptide mimetic].
    Qi J; Peng H; Gao YD; Xu C; Liang ZQ; Gu ZL; Yang CZ
    Yao Xue Xue Bao; 2003 Nov; 38(11):826-30. PubMed ID: 14991994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design.
    Casset F; Roux F; Mouchet P; Bes C; Chardes T; Granier C; Mani JC; Pugnière M; Laune D; Pau B; Kaczorek M; Lahana R; Rees A
    Biochem Biophys Res Commun; 2003 Jul; 307(1):198-205. PubMed ID: 12850000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity-determining regions (CDRs) of the monoclonal antibody 8D4: tolerance of a CDR peptide to conformational changes of a target.
    Tsumoto K; Misawa S; Ohba Y; Ueno T; Hayashi H; Kasai N; Watanabe H; Asano R; Kumagai I
    FEBS Lett; 2002 Aug; 525(1-3):77-82. PubMed ID: 12163165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downsizing antibodies: Towards complementarity-determining region (CDR)-based peptide mimetics.
    Van Holsbeeck K; Martins JC; Ballet S
    Bioorg Chem; 2022 Feb; 119():105563. PubMed ID: 34942468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of intracellular acidification on P-glycoprotein in drug-resistant K562/A02 cells].
    Lu Y; Li QH; Ma L; Li B; Yuan WS; Ru YX; Wang JX; Pang TX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):568-73. PubMed ID: 19549365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of a mimetic from an antibody complementarity-determining region.
    Saragovi HU; Fitzpatrick D; Raktabutr A; Nakanishi H; Kahn M; Greene MI
    Science; 1991 Aug; 253(5021):792-5. PubMed ID: 1876837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
    Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
    Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.
    Almagro JC; Raghunathan G; Beil E; Janecki DJ; Chen Q; Dinh T; LaCombe A; Connor J; Ware M; Kim PH; Swanson RV; Fransson J
    J Mol Recognit; 2012 Mar; 25(3):125-35. PubMed ID: 22407976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The flexibility of P-glycoprotein for its poly-specific drug binding from molecular dynamics simulations.
    Liu M; Hou T; Feng Z; Li Y
    J Biomol Struct Dyn; 2013; 31(6):612-29. PubMed ID: 22888853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
    Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
    J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combinatorial approach for the design of complementarity-determining region-derived peptidomimetics with in vitro anti-tumoral activity.
    Timmerman P; Barderas R; Desmet J; Altschuh D; Shochat S; Hollestelle MJ; Höppener JW; Monasterio A; Casal JI; Meloen RH
    J Biol Chem; 2009 Dec; 284(49):34126-34. PubMed ID: 19808684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the P-gp pump function on leukemic cell membrane and proper application of its reversal agents with Calcein-AM and flow cytometry].
    Lan ZJ; Tang YM; Shen HQ; Qian BQ; Ning BT; Chen YH
    Zhonghua Er Ke Za Zhi; 2007 May; 45(5):334-8. PubMed ID: 17697617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural evidence for a constrained conformation of short CDR-L3 in antibodies.
    Teplyakov A; Obmolova G; Malia TJ; Luo J; Gilliland GL
    Proteins; 2014 Aug; 82(8):1679-83. PubMed ID: 24470236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
    Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
    Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of substituted dibenzo[c,e]azepine-5-ones as P-glycoprotein-mediated multidrug resistance reversal agents.
    Tang X; Gu X; Ren Z; Ma Y; Lai Y; Peng H; Peng S; Zhang Y
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2675-80. PubMed ID: 22450134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design.
    Feng J; Li Y; Zhang W; Shen B
    Immunol Lett; 2005 May; 98(2):311-6. PubMed ID: 15860233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of tetrandrine combined with daunorubicin on expressions of P21 and P-gp in K562/A02 cells].
    Chen BA; Li J; Chen J; Gao F; Wu YN; Zhu MS; Ding JH; Gao C; Sun XC; Xu WL; Wang XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1179-82. PubMed ID: 19840446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-hairpin peptidomimetics: design, structures and biological activities.
    Robinson JA
    Acc Chem Res; 2008 Oct; 41(10):1278-88. PubMed ID: 18412373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modelling.
    Hou S; Li B; Wang L; Qian W; Zhang D; Hong X; Wang H; Guo Y
    J Biochem; 2008 Jul; 144(1):115-20. PubMed ID: 18424812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
    Zheng Z; Aojula H; Clarke D
    J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.